Osteoarthritis Treatment Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 - 2022, the osteoarthritis treatment market was valued at USD 5,132.4 Mn in 2015, and is expected to reach USD 5,895.5 Mn by 2022, expanding at a CAGR of 1.95% from 2016 to 2022.
Browse Full Report Visit - http://www.acutemarketreports.com/report/osteoarthritis-treatment-market
Market Insights
According to World Health Organization (WHO), Osteoarthritis (OA) is a long-term chronic disease characterized by the deterioration of cartilage in joints which results in bones rubbing together and creating stiffness, pain, and impaired movement. Furthermore, the disease most commonly affects the middle-aged and elderly, although younger people may be affected as a result of injury or overuse. Age is the strongest predictor of the disease and therefore increasing age and extended life expectancy will result in a greater occurrence of the disease. The meager treatment seeking rate is one of the main barriers to the growth of the market. Most of the medical practitioners suggested that early detection of osteoarthritis can improve patient’s quality of life but there is often a lack of awareness about the disease which requires attention. The types of therapeutics included in treatment of osteoarthritis disease are segmented as analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and hyaluronic acid. According to market experts, the non-steroidal anti-inflammatory drugs (NSAIDs) class of painkillers, such as diclofenac (150mg per day) and etoricoxib (30, 60 or 90mg per day) were found more likely to improve pain (between 95 and 100% likely) and were the top-ranked painkilling drugs. However, the major market restraint of NSAIDs market in osteoarthritis application is that its long-term use can trigger complications such as stomach ulcers, and, in rare cases may lead to heart failure.
According to World Health Organization (WHO), Osteoarthritis (OA) is a long-term chronic disease characterized by the deterioration of cartilage in joints which results in bones rubbing together and creating stiffness, pain, and impaired movement. Furthermore, the disease most commonly affects the middle-aged and elderly, although younger people may be affected as a result of injury or overuse. Age is the strongest predictor of the disease and therefore increasing age and extended life expectancy will result in a greater occurrence of the disease. The meager treatment seeking rate is one of the main barriers to the growth of the market. Most of the medical practitioners suggested that early detection of osteoarthritis can improve patient’s quality of life but there is often a lack of awareness about the disease which requires attention. The types of therapeutics included in treatment of osteoarthritis disease are segmented as analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and hyaluronic acid. According to market experts, the non-steroidal anti-inflammatory drugs (NSAIDs) class of painkillers, such as diclofenac (150mg per day) and etoricoxib (30, 60 or 90mg per day) were found more likely to improve pain (between 95 and 100% likely) and were the top-ranked painkilling drugs. However, the major market restraint of NSAIDs market in osteoarthritis application is that its long-term use can trigger complications such as stomach ulcers, and, in rare cases may lead to heart failure.
Pipeline Analysis
The phase III drugs included in the pipeline analysis are Sprifermin (Merck Serono), Invossa (TissueGene), Ampion (Ampio Pharmaceuticals. Inc.),Apitox (Apimeds, Inc.), Fasinumab (Regeneron Pharmaceuticals), LBSA0103 (LG Life Sciences), and AXS-02 (Axsome Therapeutics, Inc.). According to market experts, it was observed that the late-stage development pipeline at present includes two drugs TissueGene’s Invossa and Merck Serono’s sprifermin which are expected to launch in the US in 2020 and 2021, respectively. The III phase clinical trials studies have shown evidence of reducing disease progression, and Invossa was also found to decrease osteoarthritis pain.
The phase III drugs included in the pipeline analysis are Sprifermin (Merck Serono), Invossa (TissueGene), Ampion (Ampio Pharmaceuticals. Inc.),Apitox (Apimeds, Inc.), Fasinumab (Regeneron Pharmaceuticals), LBSA0103 (LG Life Sciences), and AXS-02 (Axsome Therapeutics, Inc.). According to market experts, it was observed that the late-stage development pipeline at present includes two drugs TissueGene’s Invossa and Merck Serono’s sprifermin which are expected to launch in the US in 2020 and 2021, respectively. The III phase clinical trials studies have shown evidence of reducing disease progression, and Invossa was also found to decrease osteoarthritis pain.
Browse All Reports of This Category - http://www.acutemarketreports.com/category/pharmaceutical-market
Key Market Movements
• Osteoarthritis is mainly prevalent in elderly persons and a significant increase in osteoarthritis incidence has occurred over the past few years assisted by rapid increase in the obese population
• Currently population of developed countries is at high risk of osteoarthritis due to increasing geriatric population
• In developing countries from Asia Pacific and Latin America the awareness related to age-specific diseases such as osteoarthritis and osteoporosis is increasing
• Osteoarthritis is mainly prevalent in elderly persons and a significant increase in osteoarthritis incidence has occurred over the past few years assisted by rapid increase in the obese population
• Currently population of developed countries is at high risk of osteoarthritis due to increasing geriatric population
• In developing countries from Asia Pacific and Latin America the awareness related to age-specific diseases such as osteoarthritis and osteoporosis is increasing
Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
Chapter 2 Executive Summary
2.1 Global Osteoarthritis TreatmentMarket Portaiture
2.2 Global Osteoarthritis Treatment Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Osteoarthritis Treatment Market, by Geography, 2015 & 2022 (USD Mn)
2.1 Global Osteoarthritis TreatmentMarket Portaiture
2.2 Global Osteoarthritis Treatment Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Osteoarthritis Treatment Market, by Geography, 2015 & 2022 (USD Mn)
Chapter 3 Osteoarthritis Treatment Market: Market Dynamics and Outlook
3.1 Osteoarthritis Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Osteoarthritis Treatment Market, 2015 (Value %)
3.1 Osteoarthritis Treatment Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Osteoarthritis Treatment Market, 2015 (Value %)
Chapter 4 Global Osteoarthritis Treatment Market, By Type of Therapeutics
4.1 Preface
4.2 Analgesics
4.3 Non-steroidal anti-inflammatory drugs (NSAIDs)
4.4 Corticosteroids
4.5 Hyaluronic Acid
4.6 Pipeline Analysis
4.6.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.6.1.1 Sprifermin
4.6.1.2 Invossa
4.6.1.3 Ampion
4.6.1.4 Apitox
4.6.1.5 Fasinumab
4.6.1.6 LBSA0103
4.6.1.7 AXS-02
4.6.2 Tabular Representation of Phase II and I Drugs
4.1 Preface
4.2 Analgesics
4.3 Non-steroidal anti-inflammatory drugs (NSAIDs)
4.4 Corticosteroids
4.5 Hyaluronic Acid
4.6 Pipeline Analysis
4.6.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.6.1.1 Sprifermin
4.6.1.2 Invossa
4.6.1.3 Ampion
4.6.1.4 Apitox
4.6.1.5 Fasinumab
4.6.1.6 LBSA0103
4.6.1.7 AXS-02
4.6.2 Tabular Representation of Phase II and I Drugs
Chapter 5 Global Osteoarthritis Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa
To Get Complete Report @ http://www.acutemarketreports.com/report/osteoarthritis-treatment-market
Chapter 6 Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 BioDelivery Sciences International, Inc.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 BioDelivery Sciences International, Inc.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
About - Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Contact Us :
Name : Chris Paul
ACUTE MARKET REPORTS
Designation : Global Sales Manager
Toll Free(US/CANADA): +1-855-455-8662
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com
Our Blog :- http://www.pdfdevices.com/
No comments:
Post a Comment